Eli Lilly and Company $LLY Shares Bought by Elevation Wealth Partners LLC

Elevation Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 155.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,388 shares of the company’s stock after buying an additional 844 shares during the period. Elevation Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $1,665,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp boosted its position in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors grew its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Eli Lilly and Company by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,191.87 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market cap of $1.12 trillion, a P/E ratio of 40.00, a P/E/G ratio of 1.41 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The firm’s 50 day moving average is $1,157.76 and its two-hundred day moving average is $1,046.57.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the company earned $6.31 EPS. The company’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts expect that Eli Lilly and Company will post 36 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Analysts Set New Price Targets

LLY has been the topic of several research reports. Truist Financial upped their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Barclays boosted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Jefferies Financial Group increased their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,293.71.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above analysts’ expectations near $20.7 billion. Adjusted EPS of $8.38 substantially exceeded the consensus estimate of $6.16. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: Mounjaro sales reportedly surged 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly sales. The performance indicates that demand for Lilly’s diabetes and weight-loss treatments remains strong and is driving the company’s earnings growth. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $85 billion-$87 billion from $82 billion-$85 billion. Management also highlighted accelerating adoption of Foundayo, broader Medicare obesity-drug access and progress toward a potential 2027 retatrutide filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analyst optimism remains elevated: Cantor Fitzgerald raised its price target to $1,410 and maintained an “overweight” rating. Coverage also emphasizes that Lilly is widening its lead over Novo Nordisk, whose recent results have raised concerns about competitive momentum. The divide between Eli Lilly and Novo Nordisk is widening
• Neutral Sentiment: Amazon’s planned $50-per-month Medicare access to Wegovy, Zepbound and Foundayo could expand distribution and patient access, but greater retail availability may also increase price competition and payer pressure.
• Negative Sentiment: Several analysts caution that Lilly’s valuation and heavy reliance on GLP-1 products leave the shares vulnerable if demand, manufacturing capacity or competitive conditions weaken.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.